Latest Pharma Insights
CMR Surgical Banks On Portability And Open Data To Crack Da Vinci-Dominated Market
CMR Surgical is entering the US surgical robotics market with a counter-intuitive playbook: complement rather than displace incumbents, lead on portability, and build a data moat through an NVIDIA partnership — while Intuitive still owns the room.
Medtech Insight - August 3, 2026
CMR Surgical is entering the US surgical robotics market with a counter-intuitive playbook: complement rather than displace incumbents, lead on portability, and build a data moat through an NVIDIA partnership — while Intuitive still owns the room.
Medtech Insight - August 3, 2026
Bristol-Zeneca? Industry May Be Poised For A Mega Merger
Bristol Myers and AstraZeneca are reported to be in merger discussions, a combination that would shake up the pharma sector.
Scrip - August 3, 2026
Bristol Myers and AstraZeneca are reported to be in merger discussions, a combination that would shake up the pharma sector.
Scrip - August 3, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets.
Scrip - August 3, 2026
In this week's episode: AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets.
Scrip - August 3, 2026
Bristol-Zeneca? Industry May Be Poised For A Mega Merger
Bristol Myers and AstraZeneca are reported to be in merger discussions, a combination that would shake up the pharma sector.
Scrip - August 3, 2026
Bristol Myers and AstraZeneca are reported to be in merger discussions, a combination that would shake up the pharma sector.
Scrip - August 3, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets.
Scrip - August 3, 2026
In this week's episode: AstraZeneca reins in AI spending; Argenx’s pipeline in a product play; GSK cutting costs amid Phase III plans; Sanofi’s pipeline reckoning; and NewCo version 2 for Chinese assets.
Scrip - August 3, 2026
CMR Surgical Banks On Portability And Open Data To Crack Da Vinci-Dominated Market
CMR Surgical is entering the US surgical robotics market with a counter-intuitive playbook: complement rather than displace incumbents, lead on portability, and build a data moat through an NVIDIA partnership — while Intuitive still owns the room.
Medtech Insight - August 3, 2026
CMR Surgical is entering the US surgical robotics market with a counter-intuitive playbook: complement rather than displace incumbents, lead on portability, and build a data moat through an NVIDIA partnership — while Intuitive still owns the room.
Medtech Insight - August 3, 2026
Retailers’ Welcome For Therabreath Toothpaste Shines On C&D’s Full-Year Outlook
“We never deserved the space that we got for the toothpaste, but because of the success of the mouthwash, we got some premium, great shelf space,” says president and CEO Richard Dierker with C&D’s second-quarter results.
HBW Insight - August 2, 2026
“We never deserved the space that we got for the toothpaste, but because of the success of the mouthwash, we got some premium, great shelf space,” says president and CEO Richard Dierker with C&D’s second-quarter results.
HBW Insight - August 2, 2026
What’s Next? Five Things To Look Out For In August
Generics Bulletin previews the most noteworthy and anticipated events for August 2026.
Generics Bulletin - August 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for August 2026.
Generics Bulletin - August 1, 2026
Quenching The Environmental Thirst Of Pharma’s AI – But No One Is Measuring It
As artificial intelligence permeates its way into drug development, driving efficiency, speed, and profits, the environmental cost remains unaccounted.
In Vivo - August 2, 2026
As artificial intelligence permeates its way into drug development, driving efficiency, speed, and profits, the environmental cost remains unaccounted.
In Vivo - August 2, 2026
The Federated Learning Wave: Part 1, The Model Goes to the Data
Federated learning promised to crack biopharma's data problem. Four years on, it's finally being built for real.
In Vivo - August 2, 2026
Federated learning promised to crack biopharma's data problem. Four years on, it's finally being built for real.
In Vivo - August 2, 2026